Poltreg S.A. (WSE: PTG)
Health Care · Biotechnology · PL
zł26.60
0.00% today · -12.8% 1Y
Poltreg S.A. (WSE: PTG) operates in the Biotechnology industry within the Health Care sector. The company is valued at $42.62M and employs 37 people.
Over the last twelve months the share price has lost 12.8%, trading between 16.00 and 31.20.
Tweenvest scores Poltreg S.A. across four factors: quality 31/100. Its strongest factor is quality.
PTG price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $42.62M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -5.86
- Dividend yield
- —
- Beta (5Y)
- 0.82
- 52-week high
- zł31.20
- 52-week low
- zł16.00
- Avg volume (3M)
- —
- Shares outstanding
- 5.92M
- Employees
- 37
- Next earnings
- —
About Poltreg S.A.
Poltreg S.A. is a biotechnology enterprise based in Gdansk, Poland, specializing in the creation of therapeutic solutions for autoimmune conditions. The company's research and development efforts are centered on harnessing T-regulatory cells to develop treatments, specifically targeting type 1 diabetes in children and multiple sclerosis.
- Founded
- 2015
- Listed since
- Nov 23, 2021
- Exchange
- Warsaw Stock Exchange
- Currency
- PLN
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.